Whalesbook
Jeevan Scientific Technology Ltd has filed its quarterly compliance report for the period ending March 31, 2026, confirming adherence to SEBI regulations for securities dematerialization. The company submitted this routine update on April 14, 2026, to all stock exchanges where its shares are listed.
CIL Securities Limited, the company's Registrar and Transfer Agent (RTA), confirmed that no dematerialization requests were received from depositories during the quarter. This suggests the company's processes for managing share ownership transfers are functioning smoothly. The report confirms compliance with SEBI (Depositories and Participants) Regulations, 2018. These filings are important for maintaining investor confidence by assuring shareholders that the company is diligently meeting its regulatory obligations.
Jeevan Scientific Technology, a clinical contract research organization (CRO) founded in 1999, has been expanding its capabilities. Earlier in 2026, the company successfully completed a US FDA Remote Regulatory Assessment for its Hyderabad facility. A ₹30.74 crore capital raising plan was also approved to support future expansion and acquisition initiatives.
For shareholders, this report reaffirms the company's commitment to regulatory compliance and transparent operations, confirming that dematerialization procedures are in order and support straightforward stock transactions.
No specific risks related to this routine compliance filing were highlighted.
The company operates within the clinical research sector, alongside peers such as Syngene International Ltd, Vimta Labs Ltd, and Suven Life Sciences Ltd. While this particular filing addresses procedural compliance rather than financial performance, adherence to regulatory standards is a critical requirement for all companies in the industry.
Investors will monitor future quarterly compliance reports for continued adherence. Key updates to watch include the utilization of the recently raised funds for expansion and acquisitions, and any further regulatory developments or assessments.